Long-term intranasal administration of fasedienol, used as-needed up to four times a day in daily life, was safe and well-tolerated in nearly 500 patients with social anxiety disorder (SAD) Patients self-administered over 30,000 doses of fasedienol in real-world settings , with a mean study

U.S. Phase 1 study with newly optimized formulation intended to facilitate Phase 2B development of itruvone as a stand-alone treatment of major depressive disorder Top line results anticipated in Q2 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 2, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that

PH80 patent portfolio now includes U.S. patents for treatment of both hot flashes and migraine SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 1, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living

Pherin acquisition completed; all future royalty payment obligations related to PH94B and PH10 eliminated, three new drug candidates added to Vistagen’s pipeline PH94B Phase 3 program for social anxiety disorder advancing towards important next steps PH10 Phase 1 study initiated to facilitate plans

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 6, 2023-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it

Acquisition eliminates all future royalty payment obligations for PH94B and PH10 and expands Vistagen's pipeline SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 2, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for

Small U.S. Phase 1 trial with newly optimized formulation to confirm favorable safety profile from three previous clinical trials and facilitate Phase 2B development of PH10 as a stand-alone treatment for major depressive disorder SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan.

Topline results of the exploratory Phase 2 clinical study anticipated in Q1 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 10, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety,

Vistagen’s recent patent filings in the U.S. and numerous additional countries mark the next step in the Company’s ongoing efforts to enhance potential commercial protection across its CNS pipeline in key pharmaceutical markets SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec.